United States · Platforms & data · TipRanks
GenFleet Advances GFH276 Combination Study in RAS-Mutant Cancers
Detailed summary
Inc. Class H ( ($HK:2595) ) has issued an announcement. GenFleet Therapeutics (Shanghai) Inc. is advancing GFH276, an oral Pan ...
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.tipranks.com)




